Cardiff Oncology, Inc.
CRDF
$1.79
-$0.03-1.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 102.50% | -0.83% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 102.50% | -0.83% | |||
| Cost of Revenue | -440.10% | -29.21% | |||
| Gross Profit | 448.16% | 29.51% | |||
| SG&A Expenses | -23.15% | 17.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -33.27% | -18.82% | |||
| Operating Income | 34.63% | 18.97% | |||
| Income Before Tax | 35.90% | 19.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 35.90% | 19.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 35.90% | 19.26% | |||
| EBIT | 34.63% | 18.97% | |||
| EBITDA | 34.88% | 19.06% | |||
| EPS Basic | 36.40% | 19.69% | |||
| Normalized Basic EPS | 36.41% | 19.69% | |||
| EPS Diluted | 36.40% | 19.69% | |||
| Normalized Diluted EPS | 36.41% | 19.69% | |||
| Average Basic Shares Outstanding | 0.83% | 0.53% | |||
| Average Diluted Shares Outstanding | 0.83% | 0.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||